RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report
We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma of the lung that continues to outlive stage IV diagnosis of non-small cell lung cancer after treatment with RRx-001, an experimental anticancer agent with epigenetic and...
Main Authors: | Christina Brzezniak, Bruno A. Schmitz, Paul G. Peterson, Aiste Degesys, Bryan T. Oronsky, Jan J. Scicinski, Scott Z. Caroen, Corey A. Carter |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2016-01-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/443605 |
Similar Items
-
Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization
by: Corey A. Carter, et al.
Published: (2016-01-01) -
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets
by: Corey A. Carter, et al.
Published: (2016-05-01) -
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001
by: Corey A. Carter, et al.
Published: (2016-03-01) -
Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors
by: Raghunand, Natarajan, et al.
Published: (2017) -
RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature
by: Vinay P. Jani, et al.
Published: (2021-04-01)